Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer

Overview

Journal Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 2015 Aug 6

PMID 26244529

Citations 97

Authors

Rosemary D Cress

Yingjia S Chen

Cyllene R Morris

Megan Petersen

Gary S Leiserowitz

Affiliations

Soon will be listed here.

Abstract

Objective: To identify characteristics associated with long-term survival for patients with epithelial ovarian cancer using the California Cancer Registry.

Methods: A descriptive analysis of survival of all California residents diagnosed with epithelial ovarian cancer between 1994 and 2001 was conducted using patients identified through the cancer registry with follow-up through 2011. Characteristics of the patients who survived more than 10 years (long-term survivors) were compared with three other cohorts: patients who survived less than 2 years, those who survived at least 2 but no more than 5 years, and those who survived at least 5 but no more than 10 years.

Results: A total of 3,582 out of 11,541 (31%, confidence interval 30.2-31.8%) of the patients survived more than 10 years. Younger age, early stage, low-grade, and nonserous histology were significant predictors of long-term survival, but long-term survivors also included women with high-risk cancer.

Conclusion: Long-term survival is not unusual in patients with epithelial ovarian cancer, even in those with high-risk disease. Many of the prognostic factors are well known, but it remains to be determined why some patients with advanced-stage high-grade cancers survive longer than others with the same histology. These findings are important for patient counseling.

Level Of Evidence: III.

Citing Articles

Genome-wide profiling of N6-methyladenosine-modified pseudogene-derived long noncoding RNAs reveals the tumour-promoting and innate immune-restraining function of RPS15AP12 in ovarian cancer.

Xu J, Ren Y, Lu J, Qin F, Yang D, Tang C Clin Transl Med. 2025; 15(3):e70249.

PMID: 40000433 PMC: 11859666. DOI: 10.1002/ctm2.70249.

tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases.

Li Y, Tong F, Wang Y, Wang J, Wu M, Li H Acta Pharm Sin B. 2024; 14(9):4102-4117.

PMID: 39309485 PMC: 11413692. DOI: 10.1016/j.apsb.2024.06.003.

Pan-immune-inflammation value: a new prognostic index in epithelial ovarian cancer.

Liao W, Li J, Feng W, Kong W, Shen Y, Chen Z BMC Cancer. 2024; 24(1):1052.

PMID: 39187781 PMC: 11345988. DOI: 10.1186/s12885-024-12809-2.

Construction of a nomogram model for predicting the outcome of debulking surgery for ovarian cancer on the basis of clinical indicators.

Si Y, Song N, Ji Y Front Oncol. 2024; 14:1421247.

PMID: 39050577 PMC: 11266020. DOI: 10.3389/fonc.2024.1421247.

Development and Internal Validation of Nomograms for Survival of Advanced Epithelial Ovarian Cancer Based on Established Prognostic Factors and Hematologic Parameters.

Said S, IntHout J, den Ouden J, Walraven J, van der Aa M, de Hullu J J Clin Med. 2024; 13(10).

PMID: 38792332 PMC: 11122536. DOI: 10.3390/jcm13102789.

References

Tingulstad S, Skjeldestad F, Halvorsen T, Hagen B . Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 2003; 101(5 Pt 1):885-91. DOI: 10.1016/s0029-7844(03)00123-6. View

Chan J, Urban R, Cheung M, Osann K, Shin J, Husain A . Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006; 95(10):1314-20. PMC: 2360593. DOI: 10.1038/sj.bjc.6603457. View

Carmen M, Birrer M, Schorge J . Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 126(3):481-90. DOI: 10.1016/j.ygyno.2012.04.021. View

Chan J, Tian C, Monk B, Herzog T, Kapp D, Bell J . Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008; 112(10):2202-10. DOI: 10.1002/cncr.23390. View

Akhtar-Danesh N, Elit L, Lytwyn A . Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: a population-based study. Gynecol Oncol. 2011; 123(2):192-5. DOI: 10.1016/j.ygyno.2011.07.098. View

McMeekin D, Burger R, Manetta A, Disaia P, Berman M . Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol. 1995; 59(1):81-6. DOI: 10.1006/gyno.1995.1271. View

Ho C, Huang Y, Chen T, Huang S, Liu F, Chang Chien C . Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol. 2004; 94(1):197-203. DOI: 10.1016/j.ygyno.2004.04.004. View

Chan J, Munro E, Cheung M, Husain A, Teng N, Berek J . Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007; 109(1):12-9. DOI: 10.1097/01.AOG.0000249610.95885.ef. View

Barlin J, Jelinic P, Olvera N, Bogomolniy F, Bisogna M, Dao F . Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol Oncol. 2012; 128(3):512-7. DOI: 10.1016/j.ygyno.2012.11.018. View

10.

Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W . Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S161-92. DOI: 10.1016/S0020-7292(06)60033-7. View

11.

McCluggage W . Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32. DOI: 10.1097/PAT.0b013e328348a6e7. View

12.

Fleming S, Kimmick G, Sabatino S, Cress R, Wu X, Trentham-Dietz A . Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study. Ann Epidemiol. 2012; 22(11):807-13. DOI: 10.1016/j.annepidem.2012.08.001. View

13.

Elattar A, Bryant A, Winter-Roach B, Hatem M, Naik R . Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011; (8):CD007565. PMC: 6457688. DOI: 10.1002/14651858.CD007565.pub2. View

14.

Landrum L, Java J, Mathews C, Lanneau Jr G, Copeland L, Armstrong D . Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013; 130(1):12-8. PMC: 4870593. DOI: 10.1016/j.ygyno.2013.04.001. View

15.

Winter 3rd W, Maxwell G, Tian C, Carlson J, Ozols R, Rose P . Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(24):3621-7. DOI: 10.1200/JCO.2006.10.2517. View

16.

Chiang Y, Chen C, Chiang C, Hsu T, Lin M, You S . Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013; 24(4):342-51. PMC: 3805915. DOI: 10.3802/jgo.2013.24.4.342. View

17.

Zhong Q, Peng H, Zhao X, Zhang L, Hwang W . Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2014; 21(1):211-20. PMC: 4286460. DOI: 10.1158/1078-0432.CCR-14-1816. View

18.

OMalley C, Cress R, Campleman S, Leiserowitz G . Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol. 2003; 91(3):608-15. DOI: 10.1016/j.ygyno.2003.08.010. View

19.

Chan J, Loizzi V, Lin Y, Osann K, Brewster W, DiSaia P . Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. Obstet Gynecol. 2003; 102(1):156-61. DOI: 10.1016/s0029-7844(03)00399-5. View

20.

Young R, Walton L, Ellenberg S, Homesley H, Wilbanks G, DECKER D . Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990; 322(15):1021-7. DOI: 10.1056/NEJM199004123221501. View